M. Pichon

888 total citations
42 papers, 690 citations indexed

About

M. Pichon is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, M. Pichon has authored 42 papers receiving a total of 690 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 10 papers in Molecular Biology and 10 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in M. Pichon's work include Estrogen and related hormone effects (10 papers), HER2/EGFR in Cancer Research (9 papers) and Monoclonal and Polyclonal Antibodies Research (6 papers). M. Pichon is often cited by papers focused on Estrogen and related hormone effects (10 papers), HER2/EGFR in Cancer Research (9 papers) and Monoclonal and Polyclonal Antibodies Research (6 papers). M. Pichon collaborates with scholars based in France, United States and Germany. M. Pichon's co-authors include Edwin Milgröm, K. Hacène, J P Basuyau, N. Eche, Jean‐Marc Riedinger, C. Pallud, A Pecking, Júlia Szekeres‐Barthó, J.-L. Floiras and P. Várga and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

M. Pichon

36 papers receiving 654 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
M. Pichon France	16	259	183	180	113	113	42	690
Norbert Lang Germany	18	210 0.8×	181 1.0×	86 0.5×	156 1.4×	121 1.1×	34	768
Ralph Hamilton United States	15	198 0.8×	397 2.2×	72 0.4×	77 0.7×	112 1.0×	26	944
Jeffrey B. Virgin United States	14	67 0.3×	473 2.6×	224 1.2×	60 0.5×	99 0.9×	23	836
Naim Shabani Germany	16	201 0.8×	449 2.5×	179 1.0×	69 0.6×	222 2.0×	34	938
Sara Frı́as Mexico	18	99 0.4×	451 2.5×	317 1.8×	136 1.2×	53 0.5×	79	885
Rita Lieberman United States	10	144 0.6×	336 1.8×	112 0.6×	79 0.7×	198 1.8×	17	659
Ludivine Dion France	18	119 0.5×	459 2.5×	197 1.1×	54 0.5×	86 0.8×	55	804
Yoshihiko Nanbu Japan	20	144 0.6×	444 2.4×	205 1.1×	43 0.4×	260 2.3×	28	1.2k
C.E. Patek United Kingdom	18	171 0.7×	644 3.5×	195 1.1×	73 0.6×	63 0.6×	42	907

Countries citing papers authored by M. Pichon

Since Specialization

Citations

This map shows the geographic impact of M. Pichon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Pichon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Pichon more than expected).

Fields of papers citing papers by M. Pichon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Pichon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Pichon. The network helps show where M. Pichon may publish in the future.

Co-authorship network of co-authors of M. Pichon

This figure shows the co-authorship network connecting the top 25 collaborators of M. Pichon. A scholar is included among the top collaborators of M. Pichon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Pichon. M. Pichon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rieu, V., et al.. (2013). Maladie de Lyme révélée par un bloc auriculoventriculaire. Annales françaises de médecine d’urgence. 3(4). 259–260.

Riedinger, Jean‐Marc, Gabriel Ricolleau, N. Eche, et al.. (2006). CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome: results of a French multicentric study. Annals of Oncology. 17(8). 1234–1238. 82 indexed citations

Ali, Suhail M., Francisco J. Esteva, Joseph Gligorov, et al.. (2006). Serum HER-2/neu change predicts clinical outcome to trastuzumab-based therapy. Journal of Clinical Oncology. 24(18_suppl). 500–500. 12 indexed citations

Pallud, C., J M Guinebretière, K. Hacène, et al.. (2005). Tissue expression and serum levels of the oncoprotein HER-2/neu in 157 primary breast tumours.. PubMed. 25(2B). 1433–40. 20 indexed citations

Pichon, M., et al.. (2004). Comment désinfecter les circuits d' eau? Mythes et réalités. Médecine et Maladies Infectieuses. 34. S10–S13.

Saghatchian, Mahasti, et al.. (2004). Serum HER-2 Extracellular Domain: Relationship with Clinicobiological Presentation and Prognostic Value before and after Primary Treatment in 701 Breast Cancer Patients. The International Journal of Biological Markers. 19(1). 14–22. 15 indexed citations

Pichon, M., et al.. (2004). Longitudinal changes in serum her-2/neu oncoprotein levels in trastuzumab-treated metastatic breast cancer patients. European Journal of Cancer Supplements. 2(3). 138–139. 7 indexed citations

Basuyau, J P, M P Blanc-Vincent, Jean‐Michel Bidart, et al.. (2003). Summary report of the Standards, Options and Recommendations for the use of serum tumour markers in breast cancer: 2000. British Journal of Cancer. 89(S1). S32–S34. 9 indexed citations

Pallud, C., et al.. (2002). Dosage des marqueurs tumoraux ACE, CA 15.3, CA 125 et CA 19.9 dans les liquides dˈépanchement et le LCR par immunoanalyse en phase homogène. Corrélation avec les résultats cytologiques et les concentrations sériques. Immuno-analyse & Biologie Spécialisée. 17(1). 18–25. 3 indexed citations

10.

Ferrero-Poüs, M., et al.. (2001). Serum chromogranin‐A in advanced prostate cancer. British Journal of Urology. 88(7). 790–796. 36 indexed citations

11.

Eche, N., M. Pichon, Véronique Quillien, et al.. (2001). [Standards, options and recommendations for tumor markers in colorectal cancer].. PubMed. 88(12). 1177–206. 14 indexed citations

12.

Pecking, A, et al.. (2000). [1959-1999: from serum markers to 18-FDG in oncology. The experience of the René-Huguenin Center].. PubMed. 48(9). 819–24.

13.

Basuyau, J P, M P Blanc-Vincent, Jean‐Michel Bidart, et al.. (2000). [Standards, Options and Recommendations (SOR) for tumor markers in breast cancer. SOR Working Group].. PubMed. 87(10). 723–37. 16 indexed citations

14.

Broët, Philippe, M. Pichon, H Magdelénat, et al.. (1998). [Long-term prognostic role of steroid receptors in cancer of the breast].. PubMed. 85(4). 347–52. 5 indexed citations

15.

Pallud, C., V Le Doussal, M. Pichon, et al.. (1993). Immunohistochemistry of pS2 in normal human breast and in various histological forms of breast tumours. Histopathology. 23(3). 249–256. 18 indexed citations

16.

Pichon, M. & Edwin Milgröm. (1992). Oestrogen receptor negative-progesterone receptor positive phenotype in 1,211 breast tumours. British Journal of Cancer. 65(6). 895–897. 10 indexed citations

17.

Pichon, M., C. Pallud, K. Hacène, & Edwin Milgröm. (1992). Prognostic value of progesterone receptor after long-term follow-up in primary breast cancer. European Journal of Cancer. 28(10). 1676–1680. 9 indexed citations

18.

Szekeres‐Barthó, Júlia, M.F. Reznikoff‐Etiévant, P. Várga, et al.. (1989). Lymphocytic progesterone receptors in normal and pathological human pregnancy. Journal of Reproductive Immunology. 16(3). 239–247. 69 indexed citations

19.

Guilbaud, Nicolas, et al.. (1988). Modulation of estrogen receptors by phorbol diesters in human breast MCF-7 cell line. Molecular and Cellular Endocrinology. 56(1-2). 157–163. 36 indexed citations

20.

Pichon, M.. (1953). Classification des Apocynacees: XXXVII, une espece nouvelle du genre Hunteria. Bulletin du Jardin botanique de l État a Bruxelles. 23(3/4). 391–391. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact